Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
Larimar Therapeutics (Nasdaq: LRMR) announced that data from its Phase 1 clinical trial of CTI-1601 for treating Friedreich's ataxia will be presented at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, on May 26, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced that data from its Phase 1 clinical trial of CTI-1601 for treating Friedreich's ataxia will be presented at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, on May 26, 2022. The posters will cover the increase of tissue frataxin levels post-administration and the safety and pharmacokinetics of the therapy. This highlights Larimar's focus on developing treatments for complex rare diseases and advancing its clinical programs.
Positive
- Data from the Phase 1 clinical trial of CTI-1601 will be presented, indicating ongoing development.
- Focus on treating Friedreich's ataxia shows commitment to addressing complex rare diseases.
Negative
- None.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was +3.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in two upcoming poster presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, which is taking place May 26 – 28, 2022 at the Hyatt Regency Miami in Miami, Florida.
Details on the poster presentations are shown below.
| Title: | Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia |
| Abstract Number: | 9 |
| Poster Category: | Clinical Trials and Pharmacology |
| Presenting Author: | Russell G. Clayton, D.O., Principal, Aeremedea LLC |
| Presentation Date: | May 26, 2022 |
| Presentation Time: | 1:00 – 2:30 PM ET |
| Title: | Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia |
| Abstract Number: | 10 |
| Poster Category: | Clinical Trials and Pharmacology |
| Presenting Author: | Russell G. Clayton, D.O., Principal, Aeremedea LLC |
| Presentation Date: | May 26, 2022 |
| Presentation Time: | 1:00 – 2:30 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
| Investor Contact: | Company Contact: |
| Joyce Allaire | Michael Celano |
| LifeSci Advisors | Chief Financial Officer |
| jallaire@lifesciadvisors.com | mcelano@larimartx.com |
| (212) 915-2569 | (484) 414-2715 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.